Related Experiment Video
Updated: Jun 11, 2026

Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory
Published on: October 27, 2023
A Flow Cytometry-Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells
Alex Shepherd1,2, Bigitha Bennychen1,2, Zafer Ahmed1
1Human Health Therapeutics Research Centre, National Research Council, Ottawa, ON, Canada.
Abstract:
Chimeric antigen receptors (CARs) are synthetic fusion proteins that can reprogram immune cells to target specific antigens. CAR-expressing T cells have emerged as an effective treatment method for hematological cancers; despite this success, the mechanisms and structural properties that govern CAR responses are not fully understood. Here, we provide a simple assay to assess cellular avidity using a standard flow cytometer. This assay measures the interaction kinetics of CAR-expressing T cells and targets antigen-expressing target cells. By co-culturing stably transfected CAR Jurkat cells with target positive and negative cells for short periods of time in a varying effector-target gradient, we were able to observe the formation of CAR-target cell doublets, providing a readout of actively bound cells. When using the optimized protocol reported here, we observed unique cellular binding curves that varied between CAR constructs with differing antigen binding domains. The cellular binding kinetics of unique CARs remained consistent, were dependent on specific target antigen expression, and required active biological signaling. While existing literature is not clear at this time whether higher or lower CAR cell binding is beneficial to CAR therapeutic activity, the application of this simplified protocol for assessing CAR binding could lead to a better understanding of the proximal signaling events that regulate CAR functionality. Key features • Determines CAR receptor cellular interaction kinetics using a Jurkat cell model. • Can be used for a wide variety of CAR target antigens, including both hematological and solid tumor targets. • Experiments can be performed in under two hours with no staining using a standard flow cytometer. • Requires stable CAR Jurkat cells and target cells with stable fluorescent marker expression for optimal results.
Insights
This study introduces a simple flow cytometry assay to measure chimeric antigen receptor (CAR) T-cell binding kinetics. The assay quantizes CAR-target cell interactions, aiding the understanding of CAR functionality in cancer therapy.
Area of Science:
- Immunology
- Biotechnology
- Cell Biology
Background:
- Chimeric antigen receptors (CARs) reprogram immune cells for cancer therapy, particularly in hematological malignancies.
- Understanding the mechanisms and structural properties governing CAR responses is crucial for optimizing their efficacy.
- Current knowledge gaps exist regarding the precise factors influencing CAR-mediated cellular interactions and therapeutic outcomes.
Purpose of the Study:
- To develop and validate a straightforward assay for assessing cellular avidity of CAR-expressing cells.
- To characterize the interaction kinetics between CAR-expressing T cells and target antigen-expressing cells.
- To provide a tool for better understanding CAR functionality and signaling events.
Main Methods:
- Utilized a standard flow cytometer to measure interaction kinetics between CAR-expressing Jurkat cells and target cells.
- Employed co-culture of CAR Jurkat cells with target-positive and target-negative cells under varying effector-target ratios.
- Observed the formation of CAR-target cell doublets as a readout of actively bound cells, without the need for staining.
Main Results:
- Developed a simplified assay to quantify CAR-mediated cellular binding kinetics.
- Demonstrated that binding curves varied between different CAR constructs based on antigen-binding domains.
- Confirmed that cellular binding kinetics are consistent, antigen-specific, and require active biological signaling.
Conclusions:
- The developed assay provides a simple, rapid method to assess CAR-mediated cellular avidity using flow cytometry.
- This assay can be applied to various CAR targets, including those relevant to solid tumors and hematological cancers.
- The protocol's ability to reveal unique binding curves aids in understanding CAR-target interactions and proximal signaling, potentially improving CAR-based therapies.

